Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an oral tablet for oral use. It is employed to prevent cerebral vasospasm in patients who have experienced a subarachnoid hemorrhage. The drug selectively blocks L‑type calcium channels in cerebral vessels, leading to vasodilation and improved cerebral blood flow.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for each batch.

Nimotop (nimodipine) acts on cerebral vasculature to reduce the risk of vasospasm following subarachnoid hemorrhage.

- Subarachnoid hemorrhage: prevents cerebral vasospasm and supports maintenance of cerebral blood flow.

Nimotop may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Hypotension: lower than normal blood pressure, especially when standing. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare heart attack events. - Elevated liver enzymes: possible hepatic involvement. - Allergic reaction: rash, itching, or swelling that may indicate hypersensitivity.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for adverse events. - Blood pressure monitoring: check regularly to detect hypotension. - Hepatic impairment: use with caution in patients with severe liver disease. - Cardiac conditions: avoid in uncontrolled heart failure. - CYP3A4 inhibitors: avoid concomitant use with strong inhibitors such as clarithromycin. - Renal function: adjust if significant renal impairment is present. - Store at room temperature: keep in the original pack, protect from moisture and light.

Nimotop can interact with several drug classes, requiring attention to the interaction severity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase nimodipine levels. - Concomitant antihypertensives: additive hypotensive effect. - Grapefruit juice: can raise plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Other calcium channel blockers: may enhance vasodilatory response. - Beta‑blockers: monitor for combined cardiovascular effects. - Diuretics: watch for electrolyte disturbances. - NSAIDs: may blunt antihypertensive effect.